Millipore Sigma Vibrant Logo

344096 InSolution™ Fluvastatin, Sodium Salt - CAS 93957-55-2 - Calbiochem

View Products on Sigmaaldrich.com
344096
Visualizza prezzi e disponibilità

Panoramica

Replacement Information

Tabella delle specifiche principali

CAS #Empirical Formula
93957-55-2C₂₄H₂₅FNNaO₄

Prezzi e disponibilità

Numero di catalogo DisponibilitàConfezionamento Qtà/conf Prezzo Quantità
344096-10MG
Verifica della disponibilità in corso...
Disponibilità limitata
Disponibilità limitata
A magazzino 
Fuori produzione
Disponibili quantità limitate
La disponibilità deve essere confermata
    Prodotti rimanenti: riceverà un nostro avviso
      Prodotti rimanenti: riceverà un nostro avviso
      Will advise
      Contatti il Servizio Clienti
      Contact Customer Service

      Bottiglia di vetro 10 mg
      Ricerca del prezzo in corso...
      Non è stato possibile trovare il prezzo
      La quantità minima deve essere un multiplo di
      Maximum Quantity is
      Al termine dell'ordine Maggiori informazioni
      Lei ha salvato ()
       
      Richiedi il prezzo
      Description
      OverviewA synthetic, competitive inhibitor of HMG-CoA reductase that acts as anti-hypercholesterolemic agent. Unlike Lovastatin (Cat. No. 438185), Mevastatin (Cat. No. 474700), and Simvastatin (Cat. No. 567020), it does not require activation prior to use for in vitro studies. Reduces the basal MMP-1 levels in culture media of endothelial cells in a time- and dose-dependent manner. Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-Dealkylation and β-oxidation of the side-chain also occurs. The hydroxy metabolites are also reported to have some pharmacologic activity.
      Catalogue Number344096
      Brand Family Calbiochem®
      Synonyms(±)-(3Rʹ,5Sʹ,6E)-7-(3-(4-Fluorophenyl)-1-isopropylindol-2-yl)-3,5-dihydroxy-6-heptenoate, sodium
      References
      ReferencesYamamoto, A., et al. 2001. J. Pharm. Pharmacol. 53, 227.
      Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol. 52, 145.
      Ikeda, U., et al. 2000. Hypertension 36, 325.
      Levy, R.I., et al. 1993. Circulation 87 (4 Suppl.), III45.
      Tse, F.L.S. et al. 1992. J. Clin. Pharmacol. 32, 630.
      Yuan, J., et al. 1991. Atherosclerosis 87, 147.
      Product Information
      CAS number93957-55-2
      FormLiquid
      FormulationA 10 mM (10 mg/2.13 ml) solution of Fluvastatin, Sodium Salt (344095) in H₂O.
      Hill FormulaC₂₄H₂₅FNNaO₄
      Chemical formulaC₂₄H₂₅FNNaO₄
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetHMG-CoA reductase
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Protect from Light Protect from light
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C). Aliquots are stable for up to 6 months at -70°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Numero di catalogo GTIN
      344096-10MG 04055977215199

      Documentation

      InSolution™ Fluvastatin, Sodium Salt - CAS 93957-55-2 - Calbiochem MSDS

      Titolo

      Scheda di sicurezza (MSDS) 

      InSolution™ Fluvastatin, Sodium Salt - CAS 93957-55-2 - Calbiochem Certificati d'Analisi

      TitoloNumero di lotto
      344096

      Riferimenti bibliografici

      Panoramica delle referenze
      Yamamoto, A., et al. 2001. J. Pharm. Pharmacol. 53, 227.
      Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol. 52, 145.
      Ikeda, U., et al. 2000. Hypertension 36, 325.
      Levy, R.I., et al. 1993. Circulation 87 (4 Suppl.), III45.
      Tse, F.L.S. et al. 1992. J. Clin. Pharmacol. 32, 630.
      Yuan, J., et al. 1991. Atherosclerosis 87, 147.
      Scheda tecnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision11-January-2013 JSW
      Synonyms(±)-(3Rʹ,5Sʹ,6E)-7-(3-(4-Fluorophenyl)-1-isopropylindol-2-yl)-3,5-dihydroxy-6-heptenoate, sodium
      DescriptionA synthetic, competitive inhibitor of HMG-CoA reductase that acts as anti-hypercholesterolemic agent. Unlike Lovastatin (Cat. No. 438185), Mevastatin (Cat. No. 474700), and Simvastatin (Cat. No. 567020), it does not require activation prior to use for in vitro studies. Reduces the basal MMP-1 levels in culture media of endothelial cells in a time- and dose-dependent manner. Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-Dealkylation and β-oxidation of the side-chain also occurs. The hydroxy metabolites are also reported to have some pharmacologic activity.
      FormLiquid
      FormulationA 10 mM (10 mg/2.13 ml) solution of Fluvastatin, Sodium Salt (344095) in H₂O.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number93957-55-2
      Chemical formulaC₂₄H₂₅FNNaO₄
      Structure formulaStructure formula
      Purity≥98% by HPLC
      Storage Protect from light
      Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C). Aliquots are stable for up to 6 months at -70°C.
      Toxicity Standard Handling
      ReferencesYamamoto, A., et al. 2001. J. Pharm. Pharmacol. 53, 227.
      Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol. 52, 145.
      Ikeda, U., et al. 2000. Hypertension 36, 325.
      Levy, R.I., et al. 1993. Circulation 87 (4 Suppl.), III45.
      Tse, F.L.S. et al. 1992. J. Clin. Pharmacol. 32, 630.
      Yuan, J., et al. 1991. Atherosclerosis 87, 147.